Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

 

Search in our Online Store

La Merie and PharmaPlus team up to provide No-Frills business intelligence solutions Print E-mail
15 Mar 2007

New downloadable and searchable financial deal database PharmaPlus Financials provides extracts to evaluate and analyze licensing deals over the last ten years at affordable prices



BARCELONA, Spain and HUIZEN, The Netherlands | Mar 15, 2007 |
The Business Intelligence firm La Merie S.L. and the Dutch company PharmaPlus Consultancy BV announced today their collaboration to promote PharmaPlus’ proprietary financial deal database PharmaDeal Financials. The database is available in extracts for specific themes such as Diabetes & Obesity or Big Pharma & Big Biotech. PharmaDeal Financials extracts are unique searchable licensing deal databases. Available as online downloads, the databases contain financial deal specifics including deal size, upfront and milestone payments, royalties on sales, research funding and equity. The databases are fully searchable and provide quick access to financial deal specifics on one screen. PharmaDeal Financials databases allow easy comparison of deal structures with deal history from 1996 on. The products can be obtained on La Merie’s Online Store www.pipelinereview.com.

PharmaDeal Financials complements La Merie’s R&D Competitor Analysis series providing no-frills, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at affordable prices. The information is provided in a tabular format and fully referenced. Competitor projects are described by drug codes, target or mechanism of action, class of compound or product category, company, therapeutic area, indication, R&D stage and additional comments with a hyperlink leading to the source of information. The products of the R&D Competitor Analysis series are elaborated by independent analysts of La Merie Business Intelligence and distributed by PipelineReview.com.



About La Merie


La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality information on research and development to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence. The company’s No-Frills Competitor Analysis series is published in R&D Pipeline News and is also available as individual reports on the site. For more information visit www.pipelinereview.com.


About PharmaPlus Consultancy

PharmaPlus Consultancy BV provides services on strategic alliances (licensing), initial market studies and project management for independent researches, universities and start-ups in the biotechnology and pharmaceutical field. Through the use of several internal proprietary databases, the company ensures the commercial exploitation of inventions originating from universities and
biopharmaceutical start-ups. For more information visit www.pharmaplus.nl


SOURCE: La Merie Business Intelligence





Digg!Reddit!Del.icio.us!Google!Live!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Spurl!Wists!Simpy!Newsvine!Blinklist!Furl!Fark!Blogmarks!Yahoo!Smarking!Netvouz!Shadows!RawSugar!Ma.gnolia!PlugIM!Squidoo!BlogMemes!FeedMeLinks!BlinkBits!Tailrank!linkaGoGo!Free social bookmarking plugins and extensions for Joomla! websites! title=
 

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Emerging Diabetes Drugs

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics